English
Insider transactions
EDGARKailera Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-22.
- Open-market purchases (code P)
- 5 transactions, 20,421,876 shares
- Sum of shares × price per share: 326,750,016
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–48 of 48
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-07 Filed 2026-09-09 | Nicholson Nur Officer: Chief Technology Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 220,000 | 0 | — | 220,000 | Direct (D) | No | F1
| Open filing 0001193125-26-386782 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-08 | Tregoning Kathleen Officer: See Remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 175,000 | 0 | — | 175,000 | Direct (D) | No | F1
| Open filing 0001193125-26-298558 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Renaud Ronald C JR Director · Officer: CEO President | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 38,094 | 5.25 | 199,993.5Derived: shares × price per share. Exact value 199993.50. | 38,094 | Direct (D) | No | — | Open filing 0001193125-26-267493 Read from the filing’s XML Dispute this row |
| 2026-06-09 Filed 2026-06-11 | Renaud Ronald C JR Director · Officer: CEO President | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 38,094 | 0 | — | 817,826 | Direct (D) | No | F1
| Open filing 0001193125-26-267493 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | CConversion of derivative security | Acquired (A) | 9,477,719 | — | — | 9,477,719 | Direct (D) | No | F2
| Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | CConversion of derivative security | Acquired (A) | 2,034,133 | — | — | 2,034,133 | Direct (D) | No | F2
| Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | CConversion of derivative security | Disposed (D) | 4,968,789 | 0 | — | 0 | Direct (D) | No | F2
| Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | CConversion of derivative security | Disposed (D) | 708,814 | 0 | — | 0 | Direct (D) | No | F2
| Open filing 0001104659-26-046276 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner | CConversion of derivative security | Acquired (A) | 10,276,820 | — | — | 10,276,820 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 500,000 | 16 | 8,000,000Derived: shares × price per share. Exact value 8000000. | 10,776,820 | Indirect (I) See footnote | No | F2
| Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner | CConversion of derivative security | Disposed (D) | 8,250,000 | — | — | 0 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-22 | RTW INVESTMENTS, LP 10% ownerWONG RODERICK 10% owner | CConversion of derivative security | Disposed (D) | 2,026,820 | — | — | 0 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001231919-26-000390 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Koppel Adam Director · 10% owner | CConversion of derivative security | Acquired (A) | 16,875,000 | — | — | 16,875,000 | Indirect (I) See footnotes | No | F1, F4, F5
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Koppel Adam Director · 10% owner | CConversion of derivative security | Acquired (A) | 4,145,768 | — | — | 21,020,768 | Indirect (I) See footnotes | No | F2, F4, F5
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Koppel Adam Director · 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,562,500 | 16.00 | 25,000,000Derived: shares × price per share. Exact value 25000000.00. | 22,583,268 | Indirect (I) See footnotes | No | F4, F5
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Koppel Adam Director · 10% owner | CConversion of derivative security | Disposed (D) | 16,875,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 0 | Indirect (I) See footnotes | No | F1, F4, F5
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Koppel Adam Director · 10% owner | CConversion of derivative security | Disposed (D) | 4,145,768 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 0 | Indirect (I) See footnotes | No | F2, F4, F5
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner | CConversion of derivative security | Acquired (A) | 16,875,000 | — | — | 16,875,000 | Indirect (I) See footnotes | No | F1, F3, F4
| Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner | CConversion of derivative security | Acquired (A) | 4,145,768 | — | — | 21,020,768 | Indirect (I) See footnotes | No | F2, F3, F4
| Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,562,500 | 16.00 | 25,000,000Derived: shares × price per share. Exact value 25000000.00. | 22,583,268 | Indirect (I) See footnotes | No | F3, F4
| Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner | CConversion of derivative security | Disposed (D) | 16,875,000 | 0 | — | 0 | Indirect (I) See footnotes | No | F1, F3, F4
| Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Bain Capital Life Sciences Investors, LLC 10% ownerBain Capital Life Sciences IV General Partner, LLC 10% ownerBain Capital Life Sciences Fund IV, L.P. 10% ownerBCLS Fund IV Investments GP, LLC 10% ownerBCLS Fund IV Investments, L.P. 10% owner | CConversion of derivative security | Disposed (D) | 4,145,768 | 0 | — | 0 | Indirect (I) See footnotes | No | F2, F3, F4
| Open filing 0001193125-26-164389 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Kaplan Andrew T. Director · 10% owner | CConversion of derivative security | Acquired (A) | 17,857,143 | — | — | 17,857,143 | Indirect (I) See footnotes | No | F1, F3, F4
| Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Kaplan Andrew T. Director · 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 8,398,438 | 16.00 | 134,375,008Derived: shares × price per share. Exact value 134375008.00. | 26,255,581 | Indirect (I) See footnotes | No | F3, F4
| Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | Kaplan Andrew T. Director · 10% owner | CConversion of derivative security | Disposed (D) | 17,857,143 | 0 | — | 0 | Indirect (I) See footnotes | No | F1, F3, F4
| Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner | CConversion of derivative security | Acquired (A) | 17,857,143 | — | — | 17,857,143 | Indirect (I) See footnotes | No | F1, F2, F3
| Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 8,398,438 | 16.00 | 134,375,008Derived: shares × price per share. Exact value 134375008.00. | 26,255,581 | Indirect (I) See footnotes | No | F2, F3
| Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row |
| 2026-04-20 Filed 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% ownerBain Capital XIV General Partner, LLC 10% ownerBain Capital Fund XIV, L.P. 10% ownerBCPE Perseus Investor GP, LLC 10% ownerBCPE Perseus Investor, LP 10% owner | CConversion of derivative security | Disposed (D) | 17,857,143 | 0 | — | 0 | Indirect (I) See footnotes | No | F1, F2, F3
| Open filing 0001193125-26-164417 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Coleman Jamie Beth Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 75,000 | 0 | — | 75,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164264 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Coleman Jamie Beth Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 75,000 | 0 | — | 75,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164264 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Pagan Douglas W. Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164210 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Pagan Douglas W. Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164210 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Burgess Paul D. Officer: See Remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164275 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Burgess Paul D. Officer: See Remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164275 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Akamine Scott Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 60,000 | 0 | — | 60,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164306 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Akamine Scott Officer: Chief Legal Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 60,000 | 0 | — | 60,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164306 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Clyburn Frank Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0 | — | 38,300 | Direct (D) | No | F1
| Open filing 0001193125-26-164224 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Koppel Adam Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 38,300 | Direct (D) | No | F3
| Open filing 0001193125-26-164407 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Renaud Ronald C JR Director · Officer: CEO President | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164299 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Renaud Ronald C JR Director · Officer: CEO President | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164299 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | MACKAY MARTIN Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0 | — | 38,300 | Direct (D) | No | F1
| Open filing 0001193125-26-164253 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Cloghessy Paula Officer: Chief People Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 60,000 | 0 | — | 60,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164307 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Cloghessy Paula Officer: Chief People Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 60,000 | 0 | — | 60,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164307 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Kaplan Andrew T. Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0 | — | 38,300 | Direct (D) | No | F2
| Open filing 0001193125-26-164388 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Hite Christopher Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0 | — | 38,300 | Direct (D) | No | F1
| Open filing 0001193125-26-164226 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Wasserman Scott M. Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F1
| Open filing 0001193125-26-164243 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Wasserman Scott M. Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 100,000 | 0 | — | 100,000 | Direct (D) | No | F2
| Open filing 0001193125-26-164243 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | MILLIGAN JOHN F Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,300 | 0 | — | 38,300 | Direct (D) | No | F1
| Open filing 0001193125-26-164271 Read from the filing’s XML Dispute this row |
Latest reported holdings
What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.
| Reporting owner | Security | Shares owned after | Direct or indirect | Source |
|---|---|---|---|---|
| Akamine Scott Officer: Chief Legal Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 60,000 | D | As of 2026-04-16 Open filing 4 |
| BAIN CAPITAL INVESTORS LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BAIN CAPITAL INVESTORS LLC 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments GP, LLC 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments GP, LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments GP, LLC 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments, L.P. 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments, L.P. 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCLS Fund IV Investments, L.P. 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCPE Perseus Investor GP, LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCPE Perseus Investor GP, LLC 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCPE Perseus Investor, LP 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| BCPE Perseus Investor, LP 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Fund XIV, L.P. 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Fund XIV, L.P. 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Fund IV, L.P. 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Fund IV, L.P. 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Fund IV, L.P. 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences IV General Partner, LLC 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences IV General Partner, LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences IV General Partner, LLC 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital XIV General Partner, LLC 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Bain Capital XIV General Partner, LLC 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Burgess Paul D. Officer: See Remarks | Stock Option (right to buy) Derivative security · underlying Common Stock | 100,000 | D | As of 2026-04-16 Open filing 4 |
| Cloghessy Paula Officer: Chief People Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 60,000 | D | As of 2026-04-16 Open filing 4 |
| Clyburn Frank Director | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| Coleman Jamie Beth Officer: Chief Commercial Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 75,000 | D | As of 2026-04-16 Open filing 4 |
| Hite Christopher Director | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Series A-2 convertible non-voting preferred stock Derivative security · underlying Common Stock | 0 | D | As of 2026-04-20 Open filing 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Series A-2 convertible preferred stock Derivative security · underlying Common Stock | 0 | D | As of 2026-04-20 Open filing 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Common Stock | 1 | I By Hengrui (USA) Ltd. | As of 2026-04-22 Open filing 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Common Stock | 2,034,133 | D | As of 2026-04-20 Open filing 4 |
| Kaplan Andrew T. Director · 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Kaplan Andrew T. Director · 10% owner | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| Kaplan Andrew T. Director · 10% owner | Common Stock | 26,255,581 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Koppel Adam Director · 10% owner | Series A-1 Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Koppel Adam Director · 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnotes | As of 2026-04-20 Open filing 4 |
| Koppel Adam Director · 10% owner | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| Koppel Adam Director · 10% owner | Common Stock | 22,583,268 | I See footnotes | As of 2026-04-20 Open filing 4 |
| MACKAY MARTIN Director | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| MILLIGAN JOHN F Director | Stock Option (right to buy) Derivative security · underlying Common Stock | 38,300 | D | As of 2026-04-16 Open filing 4 |
| Nicholson Nur Officer: Chief Technology Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 220,000 | D | As of 2026-09-07 Open filing 4 |
| Pagan Douglas W. Officer: Chief Financial Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 100,000 | D | As of 2026-04-16 Open filing 4 |
| RTW INVESTMENTS, LP 10% owner | Series A Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnote | As of 2026-04-20 Open filing 4 |
| RTW INVESTMENTS, LP 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnote | As of 2026-04-20 Open filing 4 |
| RTW INVESTMENTS, LP 10% owner | Common Stock | 10,776,820 | I See footnote | As of 2026-04-20 Open filing 4 |
| Renaud Ronald C JR Director · Officer: CEO President | Stock Option (right to buy) Derivative security · underlying Common Stock | 817,826 | D | As of 2026-06-09 Open filing 4 |
| Renaud Ronald C JR Director · Officer: CEO President | Common Stock | 38,094 | D | As of 2026-06-09 Open filing 4 |
| Tregoning Kathleen Officer: See Remarks | Stock Option (right to buy) Derivative security · underlying Common Stock | 175,000 | D | As of 2026-07-06 Open filing 4 |
| WONG RODERICK 10% owner | Series A Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnote | As of 2026-04-20 Open filing 4 |
| WONG RODERICK 10% owner | Series B Preferred Stock Derivative security · underlying Common Stock | 0 | I See footnote | As of 2026-04-20 Open filing 4 |
| WONG RODERICK 10% owner | Common Stock | 10,776,820 | I See footnote | As of 2026-04-20 Open filing 4 |
| Wasserman Scott M. Officer: Chief Medical Officer | Stock Option (right to buy) Derivative security · underlying Common Stock | 100,000 | D | As of 2026-04-16 Open filing 4 |
Joint filers each report the same shares, so rows are not added together.
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–50 of 132
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| Bain Capital Investors LLC | 26,255,581 SH | 299,838,735 dollars | Unchanged Prior quarter: 26,255,581 | Open filing 0001193125-26-462000 Filed 2026-11-16 Dispute this row |
| Bain Capital Life Sciences Investors, LLC | 22,583,268 SH | 257,900,921 dollars | Unchanged Prior quarter: 22,583,268 | Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row |
| RTW INVESTMENTS, LP | 10,776,820 SH | 123,071,284 dollars | Unchanged Prior quarter: 10,776,820 | Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row |
| CANADA PENSION PLAN INVESTMENT BOARD | 7,304,688 SH | 83,419,537 dollars | Unchanged Prior quarter: 7,304,688 | Open filing 0001104659-26-128255 Filed 2026-11-16 Dispute this row |
| Atlas Venture Life Science Advisors, LLC | 5,171,282 SH | 59,056,040 dollars | Unchanged Prior quarter: 5,171,282 | Open filing 0001104659-26-125242 Filed 2026-11-10 Dispute this row |
| FMR LLC Partly reported under another manager | 4,659,885 SH | 53,215,889 dollars | Higher by 689,020 Prior quarter: 3,970,865 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 4,573,014 SH | 52,223,817 dollars | Higher by 644,410 Prior quarter: 3,928,604 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,173,720 SH | 47,663,882 dollars | Higher by 965,434 Prior quarter: 3,208,286 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 3,648,133 SH | 41,661,679 dollars | Higher by 407,346 Prior quarter: 3,240,787 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| Royalty Pharma Sub-Manager, LLC Partly reported under another manager | 2,455,357 SH | 28,040,177 dollars | Unchanged Prior quarter: 2,455,357 | Open filing 0002081668-26-000021 Filed 2026-11-13 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 2,241,320 SH | 25,595,874 dollars | Higher by 1,373,160 Prior quarter: 868,160 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| Siren, L.L.C. Partly reported under another manager | 2,214,286 SH | 25,287,146 dollars | Unchanged Prior quarter: 2,214,286 | Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row |
| AMERIPRISE FINANCIAL INC Partly reported under another manager | 2,094,262 SH | 23,916,506 dollars | Higher by 1,272,931 Prior quarter: 821,331 | Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,681,786 SH | 19,205,996 dollars | Lower by 12,172 Prior quarter: 1,693,958 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,619,874 SH | 18,498,961 dollars | Lower by 32,633 Prior quarter: 1,652,507 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 1,206,848 SH | 13,785,325 dollars | Higher by 73,733 Prior quarter: 1,133,115 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Frazier Life Sciences Management, L.P. | 1,200,000 SH | 13,704,000 dollars | Higher by 100,000 Prior quarter: 1,100,000 | Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1,100,000 SH | 12,562,000 dollars | Unchanged Prior quarter: 1,100,000 | Open filing 0000908834-26-000540 Filed 2026-11-16 Dispute this row |
| Trails Edge Capital Partners, LP | 942,953 SH | 10,768,523 dollars | Lower by 41,833 Prior quarter: 984,786 | Open filing 0002077247-26-000005 Filed 2026-11-16 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 878,196 SH | 10,028,997 dollars | Not in the prior quarter’s filings read | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 858,972 SH | 9,809,460 dollars | Not in the prior quarter’s filings read | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 696,577 SH | 7,954,909 dollars | Higher by 275,543 Prior quarter: 421,034 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 631,951 SH | 7,218 dollars | Lower by 2,902,459 Prior quarter: 3,534,410 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| Vestal Point Capital, LP | 625,000 SH | 7,137,500 dollars | Higher by 50,000 Prior quarter: 575,000 | Open filing 0001974915-26-000008 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 469,584 SH | 5,362,649 dollars | Lower by 503,099 Prior quarter: 972,683 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Catalio Capital Management, LP | 468,750 SH | 5,353,125 dollars | Unchanged Prior quarter: 468,750 | Open filing 0001958125-26-000012 Filed 2026-11-16 Dispute this row |
| Aberdeen Group plc Partly reported under another manager | 432,661 SH | 4,940,989 dollars | Higher by 292,661 Prior quarter: 140,000 | Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row |
| Walleye Capital LLC | 416,853 SH | 4,760,461 dollars | Not in the prior quarter’s filings read | Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 408,261 SH | 4,662,341 dollars | Higher by 351,751 Prior quarter: 56,510 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| FEDERATED HERMES, INC. Partly reported under another manager | 403,693 SH | 4,610,174 dollars | Lower by 30,376 Prior quarter: 434,069 | Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row |
| FRANKLIN TEMPLETON INC Partly reported under another manager | 401,443 SH | 5,138,470 dollars | Higher by 1,420 Prior quarter: 400,023 | Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row |
| Cormorant Asset Management, LP Partly reported under another manager | 400,000 SH | 4,568,000 dollars | Lower by 150,000 Prior quarter: 550,000 | Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 384,636 SH | 4,392,543 dollars | Higher by 21,726 Prior quarter: 362,910 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| Jump Financial, LLC Partly reported under another manager | 381,002 SH | 4,351,042 dollars | Not in the prior quarter’s filings read | Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 361,395 SH | 4,127,131 dollars | Higher by 6,964 Prior quarter: 354,431 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| Janus Henderson Group Ltd. Partly reported under another manager | 345,848 SH | 3,949,584 dollars | Not in the prior quarter’s filings read | Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 310,269 SH | 3,543,272 dollars | Higher by 303,269 Prior quarter: 7,000 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 290,142 SH | 3,313,422 dollars | Higher by 14 Prior quarter: 290,128 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 271,912 SH | 3,105,235 dollars | Lower by 2,647,198 Prior quarter: 2,919,110 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| EXCHANGE TRADED CONCEPTS, LLC Partly reported under another manager | 260,799 SH | 2,978,325 dollars | Higher by 108,298 Prior quarter: 152,501 | Open filing 0001213900-26-113173 Filed 2026-10-28 Dispute this row |
| Point72 Asset Management, L.P. | 230,115 SH | 2,627,913 dollars | Not in the prior quarter’s filings read | Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 228,447 SH | 2,608,865 dollars | Higher by 179,223 Prior quarter: 49,224 | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 198,549 SH | 2,267,430 dollars | Not in the prior quarter’s filings read | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| SEVEN GRAND MANAGERS, LLC | 175,000 SH | 1,998,500 dollars | Unchanged Prior quarter: 175,000 | Open filing 0001420506-26-002775 Filed 2026-11-16 Dispute this row |
| ALPS ADVISORS INC | 171,739 SH | 1,961,259 dollars | Higher by 40,739 Prior quarter: 131,000 | Open filing 0001398344-26-019318 Filed 2026-11-03 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 155,399 SH | 1,774,657 dollars | Higher by 97,613 Prior quarter: 57,786 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| HRT FINANCIAL LP | 151,000 SH | 1,724 dollars | Not in the prior quarter’s filings read | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 147,192 SH | 1,680,932 dollars | Higher by 58,396 Prior quarter: 88,796 | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| Bank of New York Mellon Corp Partly reported under another manager | 140,934 SH | 1,609,466 dollars | Higher by 2,535 Prior quarter: 138,399 | Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row |
| a16z Capital Management, L.L.C. | 140,000 SH | 1,598,800 dollars | Unchanged Prior quarter: 140,000 | Open filing 0001540358-26-000014 Filed 2026-11-16 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Jupiter Topco LLC 970,857 SH
- Deep Track Capital, LP 700,000 SH
- EVENTIDE ASSET MANAGEMENT, LLC 616,720 SH
- Sixth Street Partners Management Company, L.P. 362,910 SH
- TD Asset Management Inc 147,698 SH
- Avidity Partners Management LP 80,000 SH
- Foresite Capital Management VI LLC 37,500 SH
- Universal- Beteiligungs- und Servicegesellschaft mbH 22,951 SH
- SOROS FUND MANAGEMENT LLC 20,000 SH
- D. E. Shaw Co., Inc. 17,500 SH
- Harbour Capital Advisors, LLC 16,570 SH
- VICTORY CAPITAL MANAGEMENT INC 10,306 SH
- Hudson Bay Capital Management LP 10,050 SH
- GABELLI FUNDS LLC 10,000 SH
- Penserra Capital Management LLC 4,864 SH
- DIADEMA PARTNERS LP 3,621 SH
- Persistent Asset Partners Ltd 1,765 SH
- Fortitude Family Office, LLC 32 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Institutional ownership reported on Form 13F
13F filers report holding between 63.70% and 92.19% of shares outstanding.
Quarter ending 2026-09-30, against 129,850,481 shares on the cover dated 2026-10-29.
- The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
- Neither includes holders that do not file Form 13F, or managers below the filing threshold.
| Quarter | Managers holding | Shares, at least | Shares, at most | Filings read |
|---|---|---|---|---|
| 2026-09-30 | 132 | 82,715,849 | 119,706,928 | 8,935 |
| 2026-06-30 | 102 | 81,895,810 | 117,385,656 | 9,178 |
| 2026-03-31 | 0 | 0 | 0 | 9,173 |
| 2025-12-31 | 0 | 0 | 0 | 9,222 |
| 2025-09-30 | 0 | 0 | 0 | 8,469 |
| 2025-06-30 | 0 | 0 | 0 | 8,516 |
| 2025-03-31 | 0 | 0 | 0 | 8,518 |
| 2024-12-31 | 0 | 0 | 0 | 8,580 |
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| CPP Investment Board Private Holdings (4) Inc. Common Stock, $0.00001 par value per share | 5.6 | 7,304,688 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G | Open filing 0001193125-26-352133 Dispute this row |
| Canada Pension Plan Investment Board Common Stock, $0.00001 par value per share | 5.6 | 7,304,688 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G | Open filing 0001193125-26-352133 Dispute this row |
| RTW Investments, LP Common Stock, $0.00001 par value | 8.3 | 10,776,820.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G | Open filing 0001493215-26-000151 Dispute this row |
| Roderick Wong Common Stock, $0.00001 par value | 8.3 | 10,776,820.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G | Open filing 0001493215-26-000151 Dispute this row |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Common Stock, $0.00001 par value per share | 8.9 | 11,511,853.00 | 06/30/2026 Filed 2026-08-05 | SCHEDULE 13G | Open filing 0001104659-26-090642 Dispute this row |
| BCLS Fund IV Investments, L.P. Common Stock, $0.00001 par value per share | 17.43 | 22,583,268 | 04/16/2026 Filed 2026-04-23 | SCHEDULE 13D | Open filing 0001193125-26-174330 Dispute this row |
| BCPE Perseus Investor, LP Common Stock, $0.00001 par value per share | 20.27 | 26,255,581 | 04/16/2026 Filed 2026-04-23 | SCHEDULE 13D | Open filing 0001193125-26-174293 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 258,595 |
| 2016 | 246,472 |
| 2017 | 244,814 |
| 2018 | 245,575 |
| 2019 | 238,619 |
| 2020 | 249,093 |
| 2021 | 274,850 |
| 2022 | 257,922 |
| 2023 | 253,676 |
| 2024 | 261,106 |
| 2025 | 235,525 |
| 2026 | 263,830 |
Filings made before the SEC required XML are listed, not extracted.